Meet your Match

Participants will have choice between different 'Meet your Match'-sessions on Friday 30th of June. Below you can find all professionals, divided in the round in which they are available.

Leiden, 30 June 2017 round 1: 14.00 - 15.00

Prescilla Jeurink

Senior Scientist Immunology, Danone Research
Prescilla started her scientific education in Experimental Zoology and Biotechnology at the Higher Laboratory Education in Utrecht, after which she worked for three years as a research technician at the Immunopharmacology group of the Utrecht University, headed by Prof. Dr. Frans Nijkamp. Hereafter she worked in the Cell biology and Immunology group (Wageningen University) lead by Prof. Dr. Huub Savelkoul on a PhD project entitled “Mutual influence of consumption patterns on the development of food allergy”, funded by the Allergy Consortium Wageningen. Currently, Prescilla holds a position as senior Scientist Immunology at the Immunology Platform of Nutricia Research, headed by Prof. Dr. Johan Garssen.

 

 

Stefan Braam

Stefan Braam

CEO & Co-founder, Pluriomics
Stefan Braam brings over a decade of experience in stem cell research and product development. Under his leadership the company grew from idea to international commercial organization. As key inventor of the underlying Pluriomics technologies he has been instrumental in the establishment of the company. Earlier in his career, Stefan obtained a MSc and PhD (both cum laude) in stem cell biology under supervision of Prof. Dr Mummery and obtained international experience in labs in the UK and Australia. As part of the management team he is responsible for general management, strategy, business development and IP. Stefan won the NGI venture challenge (2009), the Niaba biobusiness Masterclass (2010), published in multiple leading scientific journals, secured multiple grants and commercial research collaborations and was instrumental in Pluriomics’ pre-seed, seed and Series A financing

Dirk-Jan Opstelten

R&D Director, Hal Allergy
Dirk-Jan Opstelten is R&D Director and member of the management team of HAL Allergy BV (Leiden, the Netherlands), a biopharmaceutical company involved in the development and manufacturing of immunotherapeutic drugs for allergies. He oversees all R&D activities ranging from early research, product and clinical development (phase I-IV) up to the licensure. Prior to this position, he was Director of Project Management at HAL Allergy BV and responsible for managing strategic projects including the submission of various marketing authorization applications.

From 1998 to 2008, he worked for Crucell (now a Johnson & Johnson company) in Leiden, The Netherlands, where he held various positions with increasing leadership roles. From 2006-2008, he was Program Director for the development of recombinant blood coagulation factors. Prior to that (2001-2005) he was Director of Cell Technology and responsible for the development of cell lines and culture processes for the manufacture of vaccines and recombinant proteins based on the human PER.C6® cell line.

Dirk-Jan Opstelten received his Biology degree (1990) and PhD degree (1995) in Virology from Utrecht University (the Netherlands) and worked from 1995-1998 as a post-doc at the Karolinska Institute in Stockholm (Sweden). He has co-authored more than 20 peer-reviewed articles and book chapters and is inventor on several patent applications and 4 granted patents.

 

Leiden, 30 June 2017 round 2: 15.00 - 16.00

Hans Preusting, PhD, MBA

Hans Preusting started his own consultancy PreuConsult in 2007, but started to work as full time independent consultant in January 2016. He supports a range of Dutch and international biotech companies with their business development activities as well as with their challenges in process development and GMP manufacturing. He is also consulting for venture capitalists to support their due diligence activities for potential new investments in biotech companies.

Hans Preusting holds a PhD in Biochemistry from the university of Groningen, the Netherlands (1992) and a MBA degree from Rotterdam School of Management (2011). He has over 20 years of experience in the Life Science sector and has a track record in business development, product development and manufacturing using fermentation and cell culture techniques.

Prior to starting his own consultancy, he worked for several biotech and pharma companies in the Netherlands such uniQure, Solvay Pharmaceuticals (now Abbott), DSM Biologics and Gist-brocades (now DSM). Hans Preusting holds two patents and has published over 20 scientific articles.

 

Marco Timmers

CSO & Head of Clinical Development, Synthon Biopharmaceuticals
Within Synthon Biopharmaceuticals, Marco is responsible for the development of New Molecular Entities (New Biological Entities & New Chemical Entities) in oncology and (auto-) immune diseases. Together with his team, comprising the departments of program management, preclinical development, medicinal & protein chemistry, regulatory affairs, intellectual property and clinical development, he has focused on building an R&D pipeline around Synthon’s proprietary Antibody Drug Conjugate (ADC) platform technology, combining tumor targeting (antibodies) with highly efficacious tumor cell killing mechanisms (cytotoxins). Marco is also involved in several other innovative programs around promising chemical and biological lead compounds, which will lead to a new generation of effective, targeted medicines in Synthon’s key therapeutic areas of oncology and (auto-)immune diseases. Synthon, employing over 1400 people worldwide, with its global Headquarters in Nijmegen, NL, is in the top-15 of R&D companies in NL and in the top-3 of Life Sciences R&D companies in NL, with an annual R&D budget of over 90 million Euros. For more information: www.synthon.com.

Before joining Synthon early 2012, Marco worked at Organon/Schering-Plough/MSD for over 15 years, where he held positions of increasing responsibility, lastly as Head of Medicinal Chemistry, Proof-of-Concept Leader (up to Phase II clinical studies) and Head of Pharmacology (Endocrinology & Endocrinological Oncology). Marco was also a member of the Organon, Schering-Plough & Merck R&D management teams in NL.

Marco holds a PhD (1997) in Bio-Organic Chemistry (cum laude) from Leiden University, The Netherlands. His key competencies are: project management, (medicinal) chemistry, pharmacology, pharmaceutical R&D, antibody technology, oncology, antibody-drug-conjugates, Proof-of-Concept clinical development strategy, human resource management, coaching of multidisciplinary teams, innovation management, inspirational skills, change management.

Bastiaan van Holthe

Medical Information Officer, Roche
Bastiaan obtained a master's degree in Biomedical Sciences at Utrecht University in 2014. During his studies he combined science with subjects in business, economics and financial management. In 2014 he started his career at Roche Diagnostics NL in a marketing position (Jr. Product Manager), responsible for Point of Care Solutions. In May 2016 he switched to the Healthcare Development department, where he is now responsible for all medical affairs related to the disease areas Cardiac, Critical Care and Coagulation. In this position he is able to apply his scientific background while working for a company like Roche.
Roche is a research-oriented healthcare organization, dedicated to discovering, developing and supplying innovative products and services. The company focuses on all aspects of human health: early detection, prevention, diagnostics and treatment of diseases. Roche is the world’s biggest biotech company with distinguishing products in oncology, virology, infectious diseases, rheumatology, metabolic disorders and diseases of the central nervous system. It is also the world leader in in-vitro diagnostics. Since its foundation in 1896, its head office has been in Basel, Switzerland.

In 2016, nearly 10 billion CHF were invested in R&D. Turnover totaled over 50 billion CHF. At Roche, more than 94,000 people in 150 countries are involved in innovating healthcare on a daily basis. By preventing, treating and diagnosing a wide range of diseases, our products and services have improved health and quality of life worldwide. Roche Netherlands is part of this global healthcare organization, based in Woerden (pharmaceutical division) and Almere (Diagnostics and Diabetes Care divisions). Employees are involved in marketing, sales, professional services, clinical research or medical. No production, fundamental research or development takes place in the Netherlands.

Jumpstart your career

Join BioBusiness Summer School to jumpstart your career in Life Sciences by gaining knowledge of business aspects such as product development, IPR, finance and business models. The next edition of the summer school will be organised from 25-29 June 2018 in Amsterdam, Leiden and Utrecht, the Netherlands. Register now!

Why participate

The BioBusiness Summer School is a programme tailored to bridge the gap. By immersing yourself in the business aspects of Life Sciences during this programme, you will learn the basic knowledge of BioBusiness, gain insight in the world of Life Sciences companies, meet leading business leaders and increase your international network.

Employers meet talent

Is your organisation interested in early-career talents in Life Sciences? BioBusiness Summer School can get you in touch with business oriented PhDs, postdocs or Master students. More info can be found here.